Clinical Trial Details


Research Study Summary

Preserving Beta-Cell Function with Tocilizumab in New Onset Type 1 Diabetes (the EXTEND Study)


The healthy insulin-producing beta cells that you have left when you are first diagnosed with type 1 diabetes are precious. The aim of the EXTEND Study is to test whether a therapy called tocilizumab (Actemra®) can stop the immune system from attacking these remaining beta cells and possibly extend the ability to naturally produce insulin. Currently there are no approved treatments that are able to do this.

Participants in the EXTEND study will be randomly assigned to one of two groups. One group will be given the study drug, tocilizumab, and the other group will receive an inactive substance made to look like the study drug, called a placebo.

Tocilizumab or placebo will be given once every 4 weeks over a 24 week period. There will be a total of 7 intravenous infusions with four additional follow-up visits during the next 18 months. Total study time is 2 years.

To Learn more

CW ID: 209920
Date Last Changed: August 21, 2015

Clinical Trial Snapshot

Both Male and Female
18 to 45 Years
Overall Status
Lead Sponsor
2 Years
Facility Type


You may be eligible to participate in the EXTEND Study if you:

  • Are male or female, aged 18-45
  • Have been diagnosed with type 1 diabetes within the last 3 months
  • Are in good general health

More Info

For more information, visit


Trudy Esrey
Stanford University
300 Pasteur Drive
Stanford, CA 94305
Phone: 650-498-4450

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.